Blood
Articles in this Issue
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial
Abstract The phase 2 CLL2-BZAG trial tested a measurable residual disease (MRD)–guided combination treatment of zanubrutinib, venetoclax, and obinutuzumab after an optional bendamust...
Math models expose myeloid bias mechanisms in hematopoiesis
How I treat patients with AML using azacitidine and venetoclax
Abstract Venetoclax (VEN) received full approval in October 2020 for use in older patients who are unfit with acute myeloid leukemia (AML) combined with either hypomethylating agents...
Introduction to a How I Treat series on acute myeloid leukemia
Treatment for patients with acute myeloid leukemia (AML) is being transformed for some patients, as targeted agents increase complete remission rates and survival when appropriately applied. Although...
How I treat acute myeloid leukemia with differentiation therapy
Abstract An increasing number of acute myeloid leukemia (AML) therapeutics have been developed, not as cytotoxic therapies but rather as targeted agents able to restore the aberrant...
<i>Complement</i>ing CD20 antibodies’ effector functions
How I treat secondary acute myeloid leukemia
Abstract Secondary acute myeloid leukemia (sAML) has traditionally been used to designate any AML disease arising from an antecedent hematologic disorder or after prior cytotoxic or...
LSS-Skin Sclerosis: key addition to cGVHD assessments
Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells
Abstract Monoclonal antibodies (mAbs) improve survival of patients with mature B-cell malignancies. Fcγ receptor–dependent effector mechanisms kill tumor cells but can promote antige...
Development of the Lee Symptom Scale–Skin Sclerosis for chronic GVHD–associated sclerosis
Abstract Sclerosis is a highly morbid manifestation of chronic graft-versus-host disease (cGVHD), associated with distressing symptoms and significant long-term disability. A patient...
Megakaryocyte mitotic figures in de novo AML, myelodysplasia related, with STAG2, SRSF2, and ASXL1 comutations
How I use maintenance therapy in acute myeloid leukemia
Abstract Outcomes for acute myeloid leukemia (AML) have improved significantly in the past decade with the approval of novel therapeutics targeting diverse vulnerabilities of leukemi...
Triplets: the bright and the dark side of the moon
Zanubrutinib, venetoclax, and obinutuzumab in R/R CLL
Population dynamics modeling reveals that myeloid bias involves both HSC differentiation and progenitor proliferation biases
Abstract Aging and chronic inflammation are associated with overabundant myeloid-primed multipotent progenitors (MPPs) among hematopoietic stem and progenitor cells (HSPCs). Although...